Search

Your search keyword '"Juanitez, Anna Marie"' showing total 6 results
Start Over Author "Juanitez, Anna Marie"
6 results on '"Juanitez, Anna Marie"'

1. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease

Author

Melani, Christopher, primary, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Phelan, James D., additional, Simard, Jillian, additional, Muppidi, Jagan R., additional, Thomas, Craig J., additional, Ceribelli, Michele, additional, Tosto, Frances Anne, additional, Farah, Rafic J., additional, Lee, Seung Tae, additional, Pradhan, Amynah, additional, Juanitez, Anna Marie, additional, Steinberg, Seth M., additional, Jaffe, Elaine S., additional, Roschewski, Mark, additional, Staudt, Louis M., additional, and Wilson, Wyndham H., additional

Published
2022
Full Text
View/download PDF

2. Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy

Author

Melani, Christopher, primary, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Phelan, James D., additional, Simard, Jillian, additional, Muppidi, Jagan R., additional, Thomas, Craig J., additional, Ceribelli, Michele, additional, Tosto, Frances Anne, additional, Pradhan, Amynah, additional, Juanitez, Anna Marie, additional, Steinberg, Seth M., additional, Jaffe, Elaine S., additional, Roschewski, Mark, additional, Staudt, Louis M., additional, and Wilson, Wyndham H., additional

Published
2022
Full Text
View/download PDF

3. Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis

Author

Melani, Christopher, primary, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Miljkovic, Milos D., additional, Phelan, James D., additional, Muppidi, Jagan R., additional, Thomas, Craig J., additional, Ceribelli, Michele, additional, Juanitez, Anna Marie, additional, Pradhan, Amynah, additional, Hillsman, Amy, additional, Steinberg, Seth M., additional, Jaffe, Elaine S., additional, Roschewski, Mark, additional, Staudt, Louis M., additional, and Wilson, Wyndham H., additional

Published
2021
Full Text
View/download PDF

4. Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Author

Melani, Christopher, primary, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Miljkovic, Milos D., additional, Phelan, James D., additional, Muppidi, Jagan R., additional, Thomas, Craig J., additional, Ceribelli, Michele, additional, Tosto, Frances Anne, additional, Portell, Craig A., additional, Farah, Rafic J., additional, Lee, Seung Tae, additional, Juanitez, Anna Marie, additional, Steinberg, Seth M., additional, Jaffe, Elaine S., additional, Roschewski, Mark, additional, Staudt, Louis M., additional, and Wilson, Wyndham H., additional

Published
2020
Full Text
View/download PDF

5. Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Author

Melani, Christopher, primary, Lakhotia, Rahul, additional, Pittaluga, Stefania, additional, Miljkovic, Milos D., additional, Muppidi, Jagan R., additional, Portell, Craig A., additional, Farah, Rafic, additional, Lee, Seung Tae, additional, Juanitez, Anna Marie, additional, Chou, Lydia L., additional, Steinberg, Seth M., additional, Jaffe, Elaine S., additional, Staudt, Louis, additional, Roschewski, Mark, additional, and Wilson, Wyndham, additional

Published
2019
Full Text
View/download PDF

6. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.

Author

Melani C, Lakhotia R, Pittaluga S, Phelan JD, Huang DW, Wright G, Simard J, Muppidi J, Thomas CJ, Ceribelli M, Tosto FA, Yang Y, Xu W, Davies-Hill T, Pack SD, Peer CJ, Arisa O, Mena E, Lindenberg L, Bergvall E, Portell CA, Farah RJ, Lee ST, Pradhan A, Morrison C, Tadese A, Juanitez AM, Lu C, Jacob A, Simmons H, Figg WD, Steinberg SM, Jaffe ES, Roschewski M, Staudt LM, and Wilson WH

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Adenine analogs & derivatives, Adenine adverse effects, Adenine therapeutic use, Adenine administration & dosage, Bridged Bicyclo Compounds, Heterocyclic adverse effects, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Molecular Targeted Therapy, Prednisone adverse effects, Prednisone administration & dosage, Prednisone therapeutic use, Progression-Free Survival, Pyrazoles adverse effects, Pyrazoles therapeutic use, Pyrazoles administration & dosage, Pyrimidines adverse effects, Pyrimidines therapeutic use, Pyrimidines administration & dosage, Recurrence, Sulfonamides adverse effects, Sulfonamides administration & dosage, Sulfonamides therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Lenalidomide adverse effects, Lenalidomide administration & dosage, Lenalidomide therapeutic use, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse mortality, Piperidines adverse effects, Piperidines therapeutic use, Piperidines administration & dosage
Abstract

Background: The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting multiple survival pathways may be curative in DLBCL is unknown., Methods: We performed a single-center, phase 1b-2 study of a regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed or refractory DLBCL. In phase 1b, which included patients with DLBCL and indolent lymphomas, four dose levels of venetoclax were evaluated to identify the recommended phase 2 dose, with fixed doses of the other four drugs. A phase 2 expansion in patients with germinal-center B-cell (GCB) and non-GCB DLBCL was performed. ViPOR was administered every 21 days for six cycles., Results: In phase 1b of the study, involving 20 patients (10 with DLBCL), a single dose-limiting toxic effect of grade 3 intracranial hemorrhage occurred, a result that established venetoclax at a dose of 800 mg as the recommended phase 2 dose. Phase 2 included 40 patients with DLBCL. Toxic effects that were observed among all the patients included grade 3 or 4 neutropenia (in 24% of the cycles), thrombocytopenia (in 23%), anemia (in 7%), and febrile neutropenia (in 1%). Objective responses occurred in 54% of 48 evaluable patients with DLBCL, and complete responses occurred in 38%; complete responses were exclusively in patients with non-GCB DLBCL and high-grade B-cell lymphoma with rearrangements of MYC and BCL2 or BCL6 (or both). Circulating tumor DNA was undetectable in 33% of the patients at the end of ViPOR therapy. With a median follow-up of 40 months, 2-year progression-free survival and overall survival were 34% (95% confidence interval [CI], 21 to 47) and 36% (95% CI, 23 to 49), respectively., Conclusions: Treatment with ViPOR was associated with durable remissions in patients with specific molecular DLBCL subtypes and was associated with mainly reversible adverse events. (Funded by the Intramural Research Program of the National Cancer Institute and the National Center for Advancing Translational Sciences of the National Institutes of Health and others; ClinicalTrials.gov number, NCT03223610.)., (Copyright © 2024 Massachusetts Medical Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results